

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

NVC 雷士照明
NVC LIGHTING HOLDING LIMITED
雷士照明控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2222)

**APPOINTMENT OF DIRECTOR, APPOINTMENT OF VICE CHAIRMAN
AND CHANGE OF THE BOARD COMMITTEES**

APPOINTMENT OF DIRECTOR

The board of directors (the “**Board**”) of NVC Lighting Holding Limited (the “**Company**”) is pleased to announce that Mr. Su Ling (蘇嶺) (“**Mr. Su**”) has been appointed as an independent non-executive director of the Company.

The biography of Mr. Su is as follows:

Mr. Su, aged 51, from 1986 to 1990, he worked as an officer in the former Bureau of Drugs of the Ministry of Health; from 1992 to 1993, he served as a visiting scientist in the Center for Drug Evaluation and Research of the U.S. Food and Drug Administration; from 1996 to 1999, he served as a researcher in epidemiology of the Merck Research Laboratories of Merck & Co Inc.; from 2000 to 2002, he served as the medical director of the Merck China; from January 2003 to November 2003, he served as the senior director of global regulatory strategy of the Merck Research Laboratories of Merck & Co Inc.; from 2004 to 2007, he served as the director of the medical and drug development department in Shanghai Roche Pharmaceuticals Co., Ltd.; from 2007 to 2010, he served as the vice president and the head of the Asia-Pacific clinical research and development department in Wyeth Pharmaceutical Co., Ltd.; from 2010 to 2012, he served as the senior vice president and head of the Pharma Development Department in Greater China in Beijing Novartis Pharmaceuticals Co., Ltd.; from 2012 to 2016, he served as the life science strategic advisor in Sidley Austin LLP; from 2016 to present, he has been a venture partner of Lily Asia Ventures, the professor and the director of Institute of the Drug Regulatory Science in Shenyang Pharmaceutical University. Mr. Su graduated from Shanghai Pharmaceutical University (currently known as Fudan University) majoring in pharmacology in 1986, obtained a master degree in drug clinical research and development from University of North Carolina in 1992 and obtained a doctoral degree in epidemiology from University of North Carolina in 1996.

Save as disclosed above, Mr. Su has not held any other directorships in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas. Mr. Su does not have any relationships with other directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)), or controlling shareholders (as defined in the Listing Rules) of the Company.

Mr. Su does not have any interests in nor is he deemed to be interested in any shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the Securities and Futures Ordinance.

Mr. Su will enter into a Letter of Appointment with the Company under which he will hold office until the conclusion of the next annual general meeting. The Letter of Appointment can be terminated by either party by giving three months' written notice. Mr. Su's remuneration will be determined by the Remuneration Committee of the Board, based on the Company's revenue and comparable market statistics.

Save as disclosed above, there is no other information which is discloseable pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there are no other matters relating to the appointment of Mr. Su that need to be brought to the attention of the shareholders of the Company.

The Board welcomes Mr. Su as a member of the Board.

APPOINTMENT OF VICE CHAIRMAN AND CHANGE OF MEMBERS OF THE BOARD COMMITTEES

The Board further announces that Mr. Li Huating has been appointed as the vice chairman of the Company, Mr. Li Wei has been appointed as a member of the Remuneration Committee of the Company and the Strategy and Planning Committee of the Company and Mr. Wang Xuexian has been appointed as a member of the Strategy and Planning Committee of the Company.

By Order of the Board
NVC LIGHTING HOLDING LIMITED
Wang Donglei
Chairman

Hong Kong, 19 December 2016

As at the date of this announcement, the Board consists of the following directors:

Executive Directors:

WANG Donglei
WANG Dongming
XIAO Yu
WANG Keven Dun

Non-executive Directors:

LI Huating
LI Wei
YANG Jianwen

Independent Non-executive Directors:

LEE Kong Wai, Conway
WANG Xuexian
WEI Hongxiong
SU Ling